Home  »  Finance   »  Sarepta Therapeutics Inc. (NASDAQ: SRPT): Is Its V...

Sarepta Therapeutics Inc. (NASDAQ: SRPT): Is Its Value Too High Compared To Others?

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares, rose in value on Friday, 05/13/22, with the stock price up by 4.25% to the previous day’s close as strong demand from buyers drove the stock to $65.97.

Actively observing the price movement in the last trading, the stock closed the session at $63.28, falling within a range of $64.46 and $67.53. The value of beta (5-year monthly) was 1.25. Referring to stock’s 52-week performance, its high was $101.24, and the low was $61.28. On the whole, SRPT has fluctuated by -20.75% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Sarepta Therapeutics Inc. currently standing at about $5.90 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 28, 2022 – Mar 04, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$1.14, which is expected to increase to -$0.58 for fiscal year -$4.95 and then to about -$4.47 by fiscal year 2022. Data indicates that the EPS growth is expected to be 30.40% in 2022, while the next year’s EPS growth is forecast to be 9.70%.

Analysts have estimated the company’s revenue for the quarter at $197.38 million, with a low estimate of $182 million and a high estimate of $204 million. According to the average forecast, sales growth in current quarter could jump up 36.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $691.36 million, representing an increase of 28.00% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SRPT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SRPT currently trading nearly -10.01% and -15.52% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.99, while the 7-day volatility ratio is showing 6.51% which for the 30-day chart, stands at 4.96%. Furthermore, Sarepta Therapeutics Inc. (SRPT)’s beta value is 1.29, and its average true range (ATR) is 3.77.

A comparison of Sarepta Therapeutics Inc. (SRPT) with its peers suggests the former has fared considerably weaker in the market. SRPT showed an intraday change of 4.25% in last session, and over the past year, it shrunk by -13.25%%. In comparison, Pfizer Inc. (PFE) has moved lower at -0.93% on the day and was up 24.74% over the past 12 months. On the other hand, the price of Banco Santander S.A. (SAN) has risen 4.41% on the day. The stock, however, is off -30.73% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.

Data on historical trading for Sarepta Therapeutics Inc. (NASDAQ:SRPT) indicates that the trading volumes over the past 10 days have averaged 0.89 million and over the past 3 months, they’ve averaged 746.91K. According to company’s latest data on outstanding shares, there are 87.25 million shares outstanding.

Nearly 4.20% of Sarepta Therapeutics Inc.’s shares belong to company insiders and institutional investors own 82.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.58 million shares as on Dec 30, 2021, resulting in a short ratio of 5.69. According to the data, the short interest in Sarepta Therapeutics Inc. (SRPT) stood at 5.26% of shares outstanding as of Dec 30, 2021; the number of short shares registered in Nov 29, 2021 reached 5.45 million. The stock has fallen by -26.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SRPT stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam